01—Abstract
Summary
Summary of the 8-K filed January 13, 2026. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. ("Charles River") filed this Form 8-K on January 13, 2026 to furnish materials for its presentation at the J.P.
Morgan 44th Annual Healthcare Conference. The company stated that demand trends for its Discovery and Safety Assessment (DSA) business continued to improve throughout the second half of 2025, with a preliminary DSA net book-to-bill of approximately 1.1xa in the fourth quarter of 2025. Improvement was primarily driven by small and mid-sized biotech clients, and global biopharma net bookings also increased in the fourth quarter of 2025.
The company noted that these preliminary figures remain subject to completion of its audited 2025 results. For 2026, Charles River expects the top end of its organic revenue growth guidance ranges to be at least flat for both the consolidated outlook and the DSA segment. The company is cautiously optimistic that favorable DSA demand indicators will continue into 2026, resulting in a return to revenue growth in the second half of 2026.
Expected improvement in Manufacturing organic revenue growth is anticipated to be offset by RMS headwinds from the timing of non-human primate (NHP) shipments and CRADL occupancy. Foreign exchange is expected to be an incremental benefit of 100-150 bps to reported revenue growth. The company also expects more than $100 millionb in incremental 2026 cost savings to offset annual cost inflation until revenue growth reinvigorates.
Charles River also disclosed two acquisitions. It has signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a provider of non-human primates, for an expected total purchase price of approximately $510 millionc, closing early in the first quarter of 2026 and expected to be accretive to non-GAAP EPS by approximately $0.25 in 2026 and $0.60 in 2027.
It has also exercised its option to acquire the remaining 79% stake in PathoQuest SAS for approximately €51.6 million (about $60 milliond), expected to close by the end of the first quarter of 2026. PathoQuest is expected to generate annual revenue of approximately $15 to $20 million in 2026 and is not expected to have a material impact on 2026 or 2027 GAAP or non-GAAP results. The 2026 outlook does not yet reflect these acquisitions or planned divestitures.
02—Key points
Key Highlights
- DSA net book-to-bill preliminarily estimated at approximately 1.1x in Q4 2025, with demand trends improving throughout the second half of 2025.
- Improvement driven primarily by small and mid-sized biotech clients; global biopharma net bookings also increased in Q4 2025.
- 2026 guidance: top end of organic revenue growth ranges expected to be at least flat for both consolidated outlook and the DSA segment; return to revenue growth expected in H2 2026.
- More than $100 million in incremental 2026 cost savings expected to offset annual cost inflation.
- Agreement to acquire K.F. (Cambodia) Ltd. (non-human primate provider) for approximately $510 million, expected to close early Q1 2026 and be accretive to non-GAAP EPS by about $0.25 in 2026 and $0.60 in 2027.
- Exercised option to acquire the remaining 79% stake in PathoQuest SAS for approximately €51.6 million (about $60 million), expected to close by end of Q1 2026, with projected 2026 revenue of $15 to $20 million.
- Foreign exchange expected to add 100-150 bps to reported revenue growth in 2026.
03—Questions
Frequently Asked Questions
What did Charles River report about DSA demand in the fourth quarter of 2025?
The company stated that DSA demand trends continued to improve throughout the second half of 2025, resulting in a preliminary DSA net book-to-bill of approximately 1.1x in Q4 2025. This figure is preliminary and could change upon completion of the audited 2025 financial results.
What is the company's 2026 revenue outlook?
Charles River expects the top end of its 2026 organic revenue growth guidance ranges to be at least flat for both the consolidated business and the DSA segment. It is cautiously optimistic that favorable DSA demand indicators will continue, leading to a return to revenue growth in the second half of 2026. Manufacturing improvement is expected to be partially offset by RMS headwinds from NHP shipment timing and CRADL occupancy.
What are the terms of the K.F. (Cambodia) Ltd. acquisition?
Charles River has signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory required research, for an expected total purchase price of approximately $510 million, subject to customary closing adjustments. The deal is expected to close early in Q1 2026 and to be accretive to non-GAAP EPS by approximately $0.25 in 2026 and $0.60 in 2027. The company noted K.F. is not expected to generate meaningful third-party revenue going forward and will be integrated into the DSA segment's supply operations.
What is the PathoQuest SAS transaction and its expected financial impact?
Charles River exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS, which it does not already own, for €51.6 million (approximately $60 million), subject to customary closing adjustments. The transaction is expected to close by the end of Q1 2026. PathoQuest is expected to generate approximately $15 to $20 million in annual revenue in 2026 and will join the Biologics Testing business within Manufacturing Solutions. The company does not expect a material impact on its 2026 or 2027 GAAP or non-GAAP results.
How will the company offset cost inflation in 2026?
Charles River expects incremental cost savings in 2026 totaling more than $100 million. These savings are intended to offset annual cost inflation until revenue growth strengthens. The company also noted that its outlook does not yet reflect the potential benefit to non-GAAP operating margin from the K.F. and PathoQuest acquisitions or planned divestitures, which would collectively benefit margin once completed.
04—Continue